Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NNZ 2591

Next Previous
X
Search
Drug Profile

NNZ 2591

Alternative Names: ACP-2591; Cyclo-L-Glycyl-L-2-Allylproline; NNZ-2591

Latest Information Update: 20 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer ACADIA Pharmaceuticals; Neuren Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Alkenes; Antiparkinsonians; Behavioural disorder therapies; Cyclic peptides; Neuroprotectants; Nootropics; Piperazines; Pyrazines; Pyrroles; Small molecules; Vascular disorder therapies
  • Mechanism of Action Cell death inhibitors; Neuropeptide receptor modulators; Symporter modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pitt-Hopkins syndrome; Prader-Willi syndrome; Angelman syndrome; Telomeric 22q13 Monosomy Syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Angelman syndrome; Pitt-Hopkins syndrome; Prader-Willi syndrome; Telomeric 22q13 Monosomy Syndrome
  • Phase I Fragile X syndrome; Rett syndrome

Most Recent Events

  • 04 Dec 2024 Neuren Pharmaceuticals withdraws phase II trial in Prader-Willi syndrome (In adolescents, In children) in USA (PO), as part of a revised development strategy (NCT05879614)
  • 07 Nov 2024 Neuren Pharmaceuticals completes an end of Phase II meeting with the US FDA for the Telomeric 22q13 Monosomy Syndrome
  • 07 Nov 2024 Neuren Pharmaceuticals plans a phase III trial for Telomeric 22q13 Monosomy Syndrome

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top